University of Colorado
Anschutz Medical Campus

Institutional Biosafety Committee (IBC)
Zoom Meeting Minutes
23 February 2026
9:00-11:00am (Mountain Time)

Attendance:

Voting IBC Members:
Dr. [redacted] (HD)
Dr. [redacted] (PD)
Dr. [redacted] (LH)
Dr. [redacted] (BH)
Dr. [redacted] (MJ)
[redacted] (EK)
Dr. [redacted] (SK)
Dr. [redacted] (AL)**
Dr. [redacted] (CM)
Dr. [redacted] (Co-chair) (BM)
Dr. [redacted] (Co-chair) (TM)
Dr. [redacted] (MV)
[redacted] (ZJW)**
[redacted] (ZW)

Non-voting IBC Members/Guests:
[redacted] (AA)
[redacted] (QB)
[redacted] (JH)*
[redacted] (JW)
[redacted] (MW)
[redacted] (CW)*

I. **Call to Order:** 9:01am (Mountain Time)

II. **Conflict of Interest:**
- All present IBC members were reminded that no member of an IBC may be involved (except to provide information requested by the IBC) in the review of approval of a project in which he/she/they have been or expect(s) to have a conflict of interest—including financial interests, personal relationships, or involvement in the research. Any committee member with a conflict of interest shall abstain from the vote.

III. **Review and Approval of Previous Minutes:** 26 January 2026
The minutes were reviewed and approved by the IBC.
Approved = 14
Opposed = 0
Abstained = 0

IV. **IBC Administrative Business:**
A. IBC Administrative Changes: None
B. Protocol Closures:
i. [redacted] - # 1555
ii. [redacted] - # 1613
iii. [redacted] - # 25-1567
iv. [redacted] - # 25-0837
C. Protocol Transfers: None

Recombinant and/or Synthetic Nucleic Acid Molecules Research Applications Review:
During the review, the IBC assessed the containment levels in addition to the facilities, procedures, practices, training, and expertise of the laboratory personnel involved in recombinant and/or synthetic nucleic acid molecules research. Additionally, the IBC reviewed agent

characteristics, types of manipulations planned, sources of the inserted nucleic acid sequences, the nature of the inserted nucleic acid sequences, and whether an attempt will be made to obtain expression of a foreign gene, and, if so, the protein that will be produced. The Principal Investigator must determine the applicable section(s) of the *NIH Guidelines*.

V. New Business:

1. **Environmental Health and Safety Office Updates:** None
2. **Biosafety Office Updates:**
   i. Status update of ABSL-3 – update: BH announced that the area is still currently down and that the replacement project is still expected to take 3-6 months.

VI. Clinical Trial (Human Gene Transfer) Amendments and Notices:

1. Mathias, Marc - # 24-2596: *A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-1)* (x2)
2. Yang, Michele - # 24-1082: *A Phase 1/2/3 Open-label Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and Pharmacokinetics of Intravenous RGX-202 Gene Therapy in Males with Duchenne Muscular Dystrophy (DMD)*

VII. Clinical Trial (Human Gene Transfer) Protocol Reviews:

1. **Nelson-Taylor, Sarah - # 25-0837: PH1-YOLT-203-2001: A Randomized, Double-blind, Placebo-controlled Study followed by a Treatment Extension to Evaluate the Efficacy and Safety of YOLT-203 in Children and Adults with Primary Hyperoxaluria Type 1**
   Biosafety level: BSL-1
   NIH Section(s): III-C
   Approved = 14
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation to address minor administrative items including ensuring that proper PPE checkboxes are selected in the site-specific SOP and confirmation of the IBC protocol number.

2. **Graham, Laura - # 26-0014: AN OPEN-LABEL, MULTICENTER PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AB-3028 IN PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER (CRPC)**
   Biosafety level: BSL-2 with standard precautions
   NIH Section(s): III-C
   Approved = 14
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with no further committee concerns.

3. **Pinto, Navin - # 25-2172: An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects with Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)**
   Biosafety level: BSL-2
   NIH Section(s): III-C
   Approved = 14
   Opposed = 0
   Abstained = 0

The IBC protocol presented was approved with the recommendation to address minor administrative items including ensuring that proper PPE checkboxes are selected in the site-specific SOP.

*JH and CW left the meeting at 9:35am.

VIII. New Laboratory Protocol Reviews:

1. [redacted] **- # 1765: Genetic manipulation to understand the role of RNA and translation quality control in diabetes**
   Biosafety level: BSL-2, ABSL-1
   NIH Section(s): III-D-1, III-D-2, III-D-4, III-E-3, III-F
   Approved = 14
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation to address minor administrative items including selecting appropriate IBC protocol form checkboxes as well as providing more details regarding procedures and the research narrative.

2. [redacted] **- # 1764: Mechanisms underlying the biogenesis and function of ion channels**
   Biosafety level: BSL-2
   NIH Section(s): III-D-1, III-D-2, III-F
   Approved = 14
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation to address minor administrative items including elaborating on details in the research narrative, adding procedures, updating IBC protocol form checkboxes as needed, and adding appropriate signs and symptoms language for potentially infectious agents.

IX. De Novo Laboratory Protocol Reviews:

1. [redacted] **- # 1432: Modeling pulmonary hypertension**
   Biosafety level: BSL-2, ABSL-2
   NIH Section(s): III-D-4, III-F
   Approved = 14
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation to address minor administrative items including updating BSC details, adding details to the research narrative, and updating the biomaterials section.

2. [redacted] **- # 1420: Characterize the mechanisms of anti-cancer drugs in cancer as single and combination treatments.**
   Biosafety level: BSL-1, BSL-2, ABSL-1, ABSL-2
   NIH Section(s): III-D-1, III-D-3, III-E-1, III-F
   Approved = 14
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation to address minor administrative items including updating IBC protocol form checkboxes and research narrative details, clarifying BSC room details, updating NIH guidelines, and verifying proper import

permits/exemptions are attached as needed.

3. [redacted] **- # 1087: Interrogation of NFkB pro-inflammatory signaling in the developing lung and liver.**
   Biosafety level: BSL-2, ABSL-2
   NIH Section(s): III-D-4, III-E-3, III-F
   Approved = 14
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation to address minor administrative items including updating checkboxes and research narrative details, updating infectious agents details, and updating associated IACUC protocol expiration dates as well as BSC certification dates.

4. [redacted] **- # 1365: Understanding the role of mitochondrial dynamics in cancer**
   Biosafety level: BSL-1, BSL-2, ABSL-1
   NIH Section(s): III-D-1, III-D-2, III-D-4, III-E-1, III-F
   Approved = 14
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation for modifications required to address items including clarifying procedures, benchtop applications, downstream procedures, plasmid vector use, target administration, research narrative details, and BSC location details.

5. [redacted] **- # 1634: Immune interactions with commensal fungi in the gut**
   Biosafety level: BSL-2, ABSL-2
   NIH Section(s): III-D-1, III-D-2, III-D-4, III-F
   Approved = 14
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation to address minor administrative items including checking appropriate IBC protocol form checkboxes, updating research narrative details, adding downstream procedure details, and attaching import/exemption permit details as needed.

6. [redacted] **- # 1438: Molecular Analysis of Hemostasis and Thrombosis**
   Biosafety level: BSL-2
   NIH Section(s): III-D-1, III-D-2, III-F
   Approved = 14
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation for modifications required to address items including updating IBC protocol form checkboxes, updating procedure details, and ensuring proper PPE is selected.

**AL and ZJW left the meeting at 10:45am.

7. [redacted] **- # 1061: Lentivirus-mediated trophoblast specific gene targeting**
Biosafety level: III-D-1, III-D-2, III-D-4, III-F
NIH Section(s): BSL-2, ABSL-2
Approved = 12
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation for modifications required to address items including clarification of plasmid purchasing, updating sample analysis and disposal details, checking appropriate IBC protocol form checkboxes, updating engineering control details, and removal of dosing language related to other protocols.

8. [redacted] **- # 1644: Perinatal determinants of female fertility and reproductive longevity**
Biosafety level: III-D-1, III-D-2, III-F
NIH Section(s): BSL-2, ABSL-1
Approved = 12
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation to address minor administrative items including updating storage status of agents, providing further details regarding genes of interest, and clarifying use of human biomaterials.

X. Significant Amendment Reviews for Laboratory Protocols: None

XI. Exempt Protocols – New/Renewal: None

XII. Exempt Protocol Amendments
1. [redacted] - # 1465: *Mediators of impaired angiogenesis in severe fetal growth restriction*
2. [redacted] - # 1247: *Pathogenesis of Bacterial Infections*
3. [redacted] - # 1473: *Capillary control of cerebral blood flow, and its disruption in small vessel disease.*
4. [redacted] - # 1177: *Interferon signaling in Down syndrome and Development of p53-based cancer therapeutics*
5. [redacted] - # 1671: *Mucosal eosinophil specialization and activation.*

XIII. Additional Business:
1. TM suggested the creation of an IBC working group to create guidelines for reviewing IBC protocol applications more consistently in the future. Guidelines to be created and discussed further with the rest of the committee.

XIV. Next Meeting Scheduled: 23 March 2026, 9:00am (Mountain Time)

XV. Adjournment: 11:04am (Mountain Time)